Patient and transplantation characteristics at enrollment
| . | Severity at enrollment, N = 298 . | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Mild, n = 32 . | Moderate, n = 175 . | Severe, n = 91 . | |||||||
| n (%) . | n . | Median (range) . | n (%) . | n . | Median (range) . | n (%) . | n . | Median (range) . | |
| Age at transplantation, y | 32 | 51.5 (23.6-67.9) | 175 | 52.0 (19.9-74.0) | 91 | 51.8 (19.0-78.9) | |||
| Age at enrollment, y | 32 | 53.0 (26.0-68.0) | 175 | 53.0 (22.0-74.0) | 91 | 53.0 (20.0-79.0) | |||
| Sites | 32 | 175 | 91 | ||||||
| Fred Hutchinson Cancer Research Center | 11 (35) | 95 (54) | 51 (56) | ||||||
| University of Minnesota | 6 (19) | 22 (13) | 7 (8) | ||||||
| Dana-Faber Cancer institute | 3 (9) | 18 (10) | 14 (15) | ||||||
| Stanford University Medical Center | 9 (28) | 29 (17) | 10 (11) | ||||||
| Vanderbilt University Medical Center | 3 (9) | 11 (6) | 9 (10) | ||||||
| Donor sex | 32 | 174 | 90 | ||||||
| Female into male | 18 (56) | 42 (24) | 27 (30) | ||||||
| Other | 14 (44) | 132 (76) | 63 (70) | ||||||
| White, non-Hispanic | 30 (94) | 32 | 153 (87) | 175 | 82 (90) | 91 | |||
| Diagnosis | 32 | 175 | 91 | ||||||
| Acute leukemia (AML/ALL) | 13 (40) | 85 (49) | 37 (41) | ||||||
| Chronic leukemia (CML/CLL) | 4 (13) | 23 (13) | 12 (13) | ||||||
| MDS | 4 (13) | 30 (17) | 15 (17) | ||||||
| NHL/HD | 10 (31) | 22 (12) | 21 (23) | ||||||
| MM | 1 (3) | 11 (6) | 5 (5) | ||||||
| AA | 0 (0) | 1 (1) | 0 (0) | ||||||
| Other | 0 (0) | 3 (2) | 1 (1) | ||||||
| Disease stage | 32 | 175 | 90 | ||||||
| Early | 12 (38) | 59 (34) | 28 (31) | ||||||
| Intermediate | 18 (56) | 75 (43) | 42 (47) | ||||||
| Advanced | 2 (6) | 41 (23) | 20 (22) | ||||||
| Graft source | 32 | 175 | 91 | ||||||
| Peripheral blood | 26 (82) | 158 (90) | 83 (91) | ||||||
| BM | 3 (9) | 10 (6) | 6 (7) | ||||||
| Cord blood | 3 (9) | 7 (4) | 2 (2) | ||||||
| Transplant type | 32 | 175 | 91 | ||||||
| Myeloablative | 16 (50) | 105 (60) | 49 (54) | ||||||
| Nonmyeloablative | 16 (50) | 70 (40) | 42 (46) | ||||||
| Donor type | 32 | 173 | 91 | ||||||
| HLA-matched relative | 14 (44) | 88 (51) | 38 (42) | ||||||
| HLA-mismatched relative | 0 (0) | 4 (2) | 2 (2) | ||||||
| Unrelated donor | 18 (56) | 81 (47) | 51 (56) | ||||||
| CMV status (donor/patient) | 32 | 174 | 90 | ||||||
| +/+ | 8 (25) | 56 (32) | 26 (29) | ||||||
| +/− | 4 (13) | 13 (7) | 14 (16) | ||||||
| −/+ | 9 (28) | 50 (29) | 23 (25) | ||||||
| −/− | 11 (34) | 55 (32) | 27 (30) | ||||||
| In vivo T-cell depletion (anti-thymocyte globulin) | 5 (16) | 32 | 8 (5) | 175 | 5 (5) | 91 | |||
| GVHD prophylaxis regimens | 32 | 175 | 91 | ||||||
| CSA or tacrolimus + MTX ± others | 16 (50) | 82 (47) | 44 (48) | ||||||
| CSA or tacrolimus + MMF or sirolimus | 7 (22) | 74 (42) | 37 (41) | ||||||
| Tacrolimus + MMF + sirolimus | 2 (6) | 6 (3) | 2 (2) | ||||||
| Others | 2 (6) | 5 (3) | 3 (3) | ||||||
| . | Severity at enrollment, N = 298 . | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Mild, n = 32 . | Moderate, n = 175 . | Severe, n = 91 . | |||||||
| n (%) . | n . | Median (range) . | n (%) . | n . | Median (range) . | n (%) . | n . | Median (range) . | |
| Age at transplantation, y | 32 | 51.5 (23.6-67.9) | 175 | 52.0 (19.9-74.0) | 91 | 51.8 (19.0-78.9) | |||
| Age at enrollment, y | 32 | 53.0 (26.0-68.0) | 175 | 53.0 (22.0-74.0) | 91 | 53.0 (20.0-79.0) | |||
| Sites | 32 | 175 | 91 | ||||||
| Fred Hutchinson Cancer Research Center | 11 (35) | 95 (54) | 51 (56) | ||||||
| University of Minnesota | 6 (19) | 22 (13) | 7 (8) | ||||||
| Dana-Faber Cancer institute | 3 (9) | 18 (10) | 14 (15) | ||||||
| Stanford University Medical Center | 9 (28) | 29 (17) | 10 (11) | ||||||
| Vanderbilt University Medical Center | 3 (9) | 11 (6) | 9 (10) | ||||||
| Donor sex | 32 | 174 | 90 | ||||||
| Female into male | 18 (56) | 42 (24) | 27 (30) | ||||||
| Other | 14 (44) | 132 (76) | 63 (70) | ||||||
| White, non-Hispanic | 30 (94) | 32 | 153 (87) | 175 | 82 (90) | 91 | |||
| Diagnosis | 32 | 175 | 91 | ||||||
| Acute leukemia (AML/ALL) | 13 (40) | 85 (49) | 37 (41) | ||||||
| Chronic leukemia (CML/CLL) | 4 (13) | 23 (13) | 12 (13) | ||||||
| MDS | 4 (13) | 30 (17) | 15 (17) | ||||||
| NHL/HD | 10 (31) | 22 (12) | 21 (23) | ||||||
| MM | 1 (3) | 11 (6) | 5 (5) | ||||||
| AA | 0 (0) | 1 (1) | 0 (0) | ||||||
| Other | 0 (0) | 3 (2) | 1 (1) | ||||||
| Disease stage | 32 | 175 | 90 | ||||||
| Early | 12 (38) | 59 (34) | 28 (31) | ||||||
| Intermediate | 18 (56) | 75 (43) | 42 (47) | ||||||
| Advanced | 2 (6) | 41 (23) | 20 (22) | ||||||
| Graft source | 32 | 175 | 91 | ||||||
| Peripheral blood | 26 (82) | 158 (90) | 83 (91) | ||||||
| BM | 3 (9) | 10 (6) | 6 (7) | ||||||
| Cord blood | 3 (9) | 7 (4) | 2 (2) | ||||||
| Transplant type | 32 | 175 | 91 | ||||||
| Myeloablative | 16 (50) | 105 (60) | 49 (54) | ||||||
| Nonmyeloablative | 16 (50) | 70 (40) | 42 (46) | ||||||
| Donor type | 32 | 173 | 91 | ||||||
| HLA-matched relative | 14 (44) | 88 (51) | 38 (42) | ||||||
| HLA-mismatched relative | 0 (0) | 4 (2) | 2 (2) | ||||||
| Unrelated donor | 18 (56) | 81 (47) | 51 (56) | ||||||
| CMV status (donor/patient) | 32 | 174 | 90 | ||||||
| +/+ | 8 (25) | 56 (32) | 26 (29) | ||||||
| +/− | 4 (13) | 13 (7) | 14 (16) | ||||||
| −/+ | 9 (28) | 50 (29) | 23 (25) | ||||||
| −/− | 11 (34) | 55 (32) | 27 (30) | ||||||
| In vivo T-cell depletion (anti-thymocyte globulin) | 5 (16) | 32 | 8 (5) | 175 | 5 (5) | 91 | |||
| GVHD prophylaxis regimens | 32 | 175 | 91 | ||||||
| CSA or tacrolimus + MTX ± others | 16 (50) | 82 (47) | 44 (48) | ||||||
| CSA or tacrolimus + MMF or sirolimus | 7 (22) | 74 (42) | 37 (41) | ||||||
| Tacrolimus + MMF + sirolimus | 2 (6) | 6 (3) | 2 (2) | ||||||
| Others | 2 (6) | 5 (3) | 3 (3) | ||||||
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; CLL, chronic lymphocytic leukemia; MDS, myelodysplastic syndrome; NHL, non-Hodgkin lymphoma; HD, Hodgkin lymphoma; MM, multiple myeloma; AA, aplastic anemia; CSA, cyclosporine A; MTX, methotrexate; and MMF, mycophenolate mofetil.